About Otsuka
Business Collaborators
Central Nervous System
H. Lundbeck A/S (Denmark)
- Joint development and commercialization of ABILIFY Maintena and REXULTI / RXULTI
- Joint development and commercialization of Selincro in Japan
Teva Pharmaceutical Industries, Ltd. (Israel)
- Development and commercialization of AJOVY in Japan
UCB S.A. (Belgium), UCB Japan
- Development and commercialization of NEUPRO Patch in Japan
Sumitomo Pharma Co., Ltd. (Japan)
- Development, manufacture and commercialization of ulotaront and SEP-380135 worldwide
Click Therapeutics, Inc. (U.S.)
- Collaboration on development and commercialization of digital therapeutic application Rejoyn
Ionis Pharmaceuticals, Inc. (U.S.)
- Development, manufacture and commercialization of ulefnersen worldwide
Jolly Good Inc. (Japan)
- Joint development and commercialization of the social skills training platform using virtual reality in Japan
Ai-BrainScience Inc. (Japan)
- Commercialization of MIREVO, the neuropsychological testing program that uses Eye Tracking technology, in Japan
Oncology
Takeda Pharmaceutical Company Limited (Japan)
- Joint development and commercialization of Iclusig in ten Asian countries and regions including Japan
Pierre Fabre (France)
- Business related to Busulfex in European and South American countries
Illumina, Inc. (U.S.)
- Development and commercialization of HemeSight, IVD test kit for patients with blood cancer, in Japan
Cardiovascular and Renal
Novartis Pharma K.K.
(Japanese subsidiary of parent company in Switzerland)
(Japanese subsidiary of parent company in Switzerland)
- Co-promotion of Entresto in Japan
Esperion Therapeutics, Inc. (U.S.)
- Development and commercialization of NEXLETOL in Japan
Aurinia Pharmaceuticals, Inc. (Canada & U.S.)
- Development and commercialization of Lupkynis in Japan and Europe.
Autoimmune Therapeutic Area
Harbour BioMed(China)
- Development and commercialization of HBM7020 worldwide except for Greater China (Mainland China, Hong Kong, Taiwan and Macau)
Cantargia AB(Sweden)
- Development, manufacture and commercialization of CAN10, an IL-1RAP antibody, worldwide
Rare Diseases
Ionis Pharmaceuticals, Inc. (U.S.)
- Development and commercialization of donidalorsen in Europe and the Asia-Pacific region including Japan
Gastroenterology
Takeda Pharmaceutical Company Limited (Japan)
- Co-promotion of Takecab and Cabpirin in Japan
Ophthalmology
Senju Pharmaceutical Co., Ltd. (Japan)
- Co-promotion of Mikeluna combination ophthalmic solution, Mikelan ophthalmic solution, Mikelan LA ophthalmic solution, AIBETA combination ophthalmic solution and AILAMIDE combination ophthalmic suspension in Japan
4D Molecular Therapeutics, Inc.(U.S.)
- Development and commercialization of 4D-150 in Asia-Oceania region, including Japan
Diagnostics
Eiken Chemical Co., Ltd. (Japan)
- Co-marketing of RAPIRUN and Uropaper
- Joint research and development of diagnostics
Denka Co., Ltd. (Japan)
- License for Quick Navi series